- Home
- RARE vs PTRN Comparison
RARE vs PTRN Comparison
Compare RARE & PTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | PTRN |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RARE | PTRN |
|---|---|---|
| Price | $21.26 | $10.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 10 |
| Target Price | ★ $66.32 | $19.89 |
| AVG Volume (30 Days) | ★ 2.0M | 795.7K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | N/A |
| Revenue This Year | $13.40 | $39.63 |
| Revenue Next Year | $42.83 | $24.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.13 | N/A |
| 52 Week Low | $18.41 | $9.19 |
| 52 Week High | $40.54 | $20.10 |
Technical Indicators
Market Signals| Indicator | RARE | PTRN |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 44.33 |
| Support Level | $19.61 | $9.19 |
| Resistance Level | $25.46 | $15.09 |
| Average True Range (ATR) | 0.98 | 0.83 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 39.06 | 54.39 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About PTRN Pattern Group Inc.
Pattern Group Inc is an ecommerce accelerator, uses its technology platform, data science and a team of experts to drive growth for brands. The Company acquires inventory from brand partners to sell to consumers, enabling full control over content, pricing, logistics and customer service. Brand partners that contract with the Company operate in various industries including health and wellness, beauty and personal care, home and lifestyle, pet, sports and outdoors and consumer electronics.